文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)作为早发性动脉粥样硬化外周动脉疾病的独特首要危险因素。

Lipoprotein(a) as a unique primary risk factor for early atherosclerotic peripheral arterial disease.

机构信息

General Surgery, Tripler Army Medical Center, Honolulu, HI, USA

Family Medicine, Tripler Army Medical Center, Honolulu, HI, USA.

出版信息

BMJ Case Rep. 2021 Jun 30;14(6):e243231. doi: 10.1136/bcr-2021-243231.


DOI:10.1136/bcr-2021-243231
PMID:34193454
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8246288/
Abstract

Elevated plasma lipoprotein(a) is a relatively common condition that contributes to many cardiovascular diseases. However, the awareness and testing for this condition remain low. Herein, we present a case of an otherwise healthy and active man who developed symptoms of peripheral arterial disease starting at age 49, and was found to have hyper-lipoprotein(a) as his only notable risk factor. Diagnosis was not made until years later, after an extensive workup. Upon further screening, he was also found to have subclinical coronary and carotid artery atherosclerotic disease. The patient was treated with aspirin, statin, niacin and angioplasty to bilateral superficial femoral arteries with good symptom resolution. Early screening of his son also revealed a similarly elevated lipoprotein(a) level. It is important to raise awareness of this condition and its relationship to early-onset peripheral arterial disease so patients and their families can be appropriately identified, counselled and treated.

摘要

血浆脂蛋白(a)水平升高是一种较为常见的情况,可导致多种心血管疾病。然而,人们对此种情况的认识和检测仍很低。在此,我们报告了 1 例 49 岁起出现外周动脉疾病症状的平素健康活跃的男性患者,其唯一显著的危险因素是高脂蛋白(a)血症。在经过广泛的检查后,多年后才做出诊断。进一步筛查发现,他还患有亚临床冠状动脉和颈动脉粥样硬化性疾病。患者接受了阿司匹林、他汀类药物、烟酸和双侧股浅动脉血管成形术治疗,症状得到了很好的缓解。对他儿子的早期筛查也显示出类似的脂蛋白(a)水平升高。提高对此种情况及其与早发性外周动脉疾病关系的认识很重要,以便能够适当地识别、咨询和治疗患者及其家属。

相似文献

[1]
Lipoprotein(a) as a unique primary risk factor for early atherosclerotic peripheral arterial disease.

BMJ Case Rep. 2021-6-30

[2]
Subclinical peripheral arterial disease in rheumatoid arthritis.

Atherosclerosis. 2010-5-12

[3]
2017 Taiwan lipid guidelines for high risk patients.

J Formos Med Assoc. 2017-4

[4]
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.

Am Heart J. 2011-2-2

[5]
[ESC guidelines 2017 on peripheral arterial diseases : Summary of the most important recommendations and innovations].

Herz. 2017-12

[6]
Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis.

Clin Cardiol. 2019-8-1

[7]
Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.

Ont Health Technol Assess Ser. 2010

[8]
Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.

Atheroscler Suppl. 2017-11

[9]
Arterial Atherosclerosis: Vascular Surgery Interventions.

Am Fam Physician. 2022-1-1

[10]
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.

Ann Vasc Surg. 2020-11

引用本文的文献

[1]
Statins and Peripheral Arterial Disease: A Narrative Review.

Front Cardiovasc Med. 2021-11-22

本文引用的文献

[1]
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.

J Cardiovasc Med (Hagerstown). 2021-3-1

[2]
Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?

Cardiol Clin. 2018-5

[3]
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.

Clin Cardiol. 2018-3

[4]
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.

Crit Rev Clin Lab Sci. 2017-12-20

[5]
Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.

J Clin Lipidol. 2017-7-22

[6]
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

Clin Sci (Lond). 2017-2-1

[7]
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.

Atherosclerosis. 2017-1

[8]
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Lancet. 2016-9-21

[9]
Lipoprotein apheresis to treat elevated lipoprotein (a).

J Lipid Res. 2016-10

[10]
Epidemiology of peripheral artery disease.

Circ Res. 2015-4-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索